Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;44(8):884-888.
doi: 10.1002/cac2.12589. Epub 2024 Jul 6.

Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity

Sung Hee Choi  1   2 , Jay Thomas Myers  1 , Suzanne Louise Tomchuck  1 , Melissa Bonner  3 , Saada Eid  1 , Daniel Tyler Kingsley  3 , Kristen Ashley VanHeyst  1   2 , Seong-Jin Kim  4 , Byung-Gyu Kim  1   2 , Alex Yee-Chen Huang  1   2   3   5
Affiliations

Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity

Sung Hee Choi et al. Cancer Commun (Lond). 2024 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

S.J.K declares a personal financial interest as a shareholder in TheragenEtex and Medpacto Inc. and is an employee of Medpacto Inc..

Figures

FIGURE 1
FIGURE 1
Vactosertib inhibits osteosarcoma cell growth in vitro and in vivo. (A) Kaplan‐Meier overall survival curves of high‐grade osteosarcoma patients and their expression of TGF‐β1 in clinical biopsies. Data were obtained from “R2: Genomics analysis and visualization platform” [http://r2.amc.nl]. Datasets provided by Kuijer (n = 88). The red line indicates high expression of TGF‐β1 (n = 26), while the blue line indicates low expression of TGF‐β1 (n = 62). Kaplan‐Meier curves showed worse overall survival rates of osteosarcoma patients with high TGF‐β expression compared to patients with low TGF‐β1 expression (P = 0.032). (B) Effects of vactosertib on osteosarcoma proliferation. Various doses of vactosertib (10×10−3 µmol/L to 10 µmol/L) were incubated with mOS (K7, K7M2, mOS493, and mOS482) or hOS (M132 and SAOS2). Cell growth was quantified over a 4‐day period using the IncuCyte Imaging System. The non‐linear regression (curve fit) equation was calculated using GraphPad prism (n = 5/group). (C) Vactosertib inhibits TGF‐β1 signaling pathway in osteosarcoma cells. Various doses of vactosertib (1×10−2 µmol/L to 1 µmol/L) were used to treat in K7, K7M2, mOS493, mOS482, SAOS2 and M132 cells 15 minutes before TGF‐β1 (5 ng/ml) treatment. 1 hour after TGF‐β1 treatment, cells were harvested and p‐Smad2, Smad2 and β‐actin expressions were measured by Western blot analysis. TGF‐β1 (5 ng/ml) or TGF‐β1 (5 ng/ml) / vactosertib (Vacto) (1×10−1 µmol/L) were used to treat various osteosarcoma (SAOS2, M132, K7M2, K7) for 24 hours and c‐Myc and β‐actin protein expressions were measured by Western blot analysis. (D) RNA‐sequencing analysis of human osteosarcoma (SAOS2) cells after TGF‐β1 (5 ng/ml), TGF‐β1+ vactosertib (1×10−1 µmol/L) or untreated (UT) for 24 hours. GSEA enrichment plot of c‐Myc target v1 and v2 pathway in TGF‐β1 treatment versus untreated and in TGF‐β1 + Vacto vs TGF‐β1. P values are < 0.001 and FWER is < 0.001 for both analyses. (E‐G) Vactosertib inhibited OS cell growth in vivo. (E) BALB/c mice were inoculated with 1×106 K7M2 (s.c.) on Day 0, and then treated with vehicle (p.o.) or vactosertib (50 mg/kg, p.o. 5 days/week) starting on day 11. (F) tumor sizes were measured by caliper. n = 4, ***P < 0.001 using a two‐way ANOVA between groups followed by post‐hoc Bonferroni's multiple comparison tests. (G) Tumor weight was measured (n = 4). (H‐J) Vactosertib inhibits mouse pOS development in vivo. (H) BALB/c mice were inoculated with 1×106 K7M2‐Luc (i.v.) on day 0, and then treated with vehicle (p.o.) or vactosertib (25 mg/kg p.o. 5 days/week) starting on day 7. (I) BLI was measured once a week. (J) Relative mRNA expression of GP70 and c‐Myc in lung samples of the vehicle or vactosertib‐treated mice on day 42 days after tumor injection compared with that of control lungs of no tumor‐bearing mice. n = 5/group, *P < 0.05 using an unpaired two‐tailed t‐test. (K‐L) BALB/c mice were inoculated with 1×106 K7M2‐Luc (i.v.) on Day 0, and then treated with vehicle (p.o) or vactosertib (50 mg/kg, p.o. 5 days/week) starting on day 28 (4 weeks). Ten weeks after tumor injection, lung samples were collected. (K) FACS was performed and expression of CD3, CD4, CD8, NK (CD49b), PD‐1 and IFNγ was determined by FACS. Unbiased immune cell profiling on 5000 live CD45.2 cells by t‐SNE analysis was performed. tSNE density plots of live cells in vehicle or vactosertib‐treated samples. The frequency of T cell markers by conventional FACS analysis. Vehicle n = 4, vactosertib n = 7 *P < 0.05, ***P < 0.001, using an unpaired two‐tailed t‐test. (L) Examined for expression of F4/80, PD‐L1, CD206 and Arg1 by FACS. tSNE density plots of CD45.2+ cells in vehicle or vactosertib‐treated samples. The frequency of myeloid cell markers by conventional FACS analysis. Vehicle n = 4‐7, vactosertib n = 7‐9, *P < 0.05, **P < 0.01 using an unpaired two‐tailed t‐test. Abbreviations: BLI, bioluminescent imaging; c‐Myc, cellular‐Myelocytomatosis; FACS, fluorescence‐activated cell sorting; hOS: human osteosarcoma; p.o., per os; PD‐1, Programmed death 1; PD‐L1, programmed death‐ligand 1; RNA‐seq, RNA sequence; s.c., subcutaneous; TGF‐β1, Transforming growth factor‐beta 1; tSNE, t‐distributed stochastic neighbor embedding; UT, untreated; Vacto, vactosertib.
See this image and copyright information in PMC

Update of

References

    1. Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus‐Garcia R, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol. 2006;24(7):1161–1168. - PubMed
    1. Xu S, Yang S, Sun G, Huang W, Zhang Y. Transforming growth factor‐beta polymorphisms and serum level in the development of osteosarcoma. DNA Cell Biol. 2014;33(11):802–806. - PubMed
    1. Kim BG, Malek E, Choi SH, Ignatz‐Hoover JJ, Driscoll JJ. Novel therapies emerging in oncology to target the TGF‐beta pathway. J Hematol Oncol. 2021;14(1):55. - PMC - PubMed
    1. Son JY, Park SY, Kim SJ, Lee SJ, Park SA, Kim MJ, et al. EW‐7197, a novel ALK‐5 kinase inhibitor, potently inhibits breast to lung metastasis. Mol Cancer Ther. 2014;13(7):1704–1716. - PubMed
    1. de Oliveira Rodrigues MT, Pereira da Silva L, Pogue RE, de Carvalho JL, Motoyama AB, de Alencar EST, et al. Induced resistance to ifosfamide in osteosarcoma cells suggests a more aggressive tumor profile. Biochem Biophys Rep. 2022;32:101357. - PMC - PubMed

Substances

LinkOut - more resources